Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciClone Pharma Gains China Rights for Two CV Drugs in $50 Million Deal

publication date: Dec 18, 2014
SciClone Pharma in-licensed China marketing rights to two cardiovascular drugs from The Medicines Company, a deal that includes up to $50.5 million in upfront and milestone payments. SciClone is based in California, though it focuses on the China market. Over the past two years, SciClone has been actively developing its cardiovascular portfolio: in 2013, the company acquired China rights for two other CV drugs, both of which await CFDA approval. More details....

Stock Symbols: (NSDQ: SCLN) (NSDQ: MDCO)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital